miR-205 mediates adaptive resistance to MET inhibition via ERRFI1 targeting and raised EGFR signaling by C. Migliore et al.
Research Article
miR-205 mediates adaptive resistance to MET
inhibition via ERRFI1 targeting and raised
EGFR signaling
Cristina Migliore1,2,* , Elena Morando2, Elena Ghiso2, Sergio Anastasi3, Vera P Leoni4, Maria Apicella2,
Davide Cora’1,2,5, Anna Sapino2,6, Filippo Pietrantonio7,8, Filippo De Braud7,8, Amedeo Columbano4,
Oreste Segatto3,** & Silvia Giordano1,2,***
Abstract
The onset of secondary resistance represents a major limitation to
long-term efficacy of target therapies in cancer patients. Thus, the
identification of mechanisms mediating secondary resistance is
the key to the rational design of therapeutic strategies for resis-
tant patients. MiRNA profiling combined with RNA-Seq in MET-
addicted cancer cell lines led us to identify the miR-205/ERRFI1
(ERBB receptor feedback inhibitor-1) axis as a novel mediator of
resistance to MET tyrosine kinase inhibitors (TKIs). In cells resistant
to MET-TKIs, epigenetically induced miR-205 expression deter-
mined the downregulation of ERRFI1 which, in turn, caused EGFR
activation, sustaining resistance to MET-TKIs. Anti-miR-205 trans-
duction reverted crizotinib resistance in vivo, while miR-205
over-expression rendered wt cells refractory to TKI treatment.
Importantly, in the absence of EGFR genetic alterations, miR-205/
ERRFI1-driven EGFR activation rendered MET-TKI-resistant cells
sensitive to combined MET/EGFR inhibition. As a proof of concept
of the clinical relevance of this new mechanism of adaptive resis-
tance, we report that a patient with a MET-amplified lung adeno-
carcinoma displayed deregulation of the miR-205/ERRFI1 axis in
concomitance with onset of clinical resistance to anti-MET
therapy.
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Introduction
MET is the receptor tyrosine kinase (RTK) for hepatocyte growth
factor (HGF). MET triggering by HGF engagement activates a
complex cellular program termed invasive growth, which protects
from apoptosis and drives cells to proliferate and invade the
surrounding tissues (Gherardi et al, 2012; De Silva et al, 2017).
While physiologically required for tissue patterning during embry-
onic development and tissue homeostasis in post-natal life, the
MET-driven invasive growth program can be also exploited by
cancer cells in their quest to acquire growth autonomy and meta-
static capabilities (Gherardi et al, 2012; De Silva et al, 2017).
MET over-expression linked to constitutive signaling is observed
in several tumors, including gastric, lung, ovarian, renal, thyroid,
liver, and esophageal cancers (Ghiso & Giordano, 2013). It may be
caused by diverse mechanisms (hypoxia, activation of upstream
genes, miRNA deregulation or MET gene amplification/exon 14
skipping mutations) and can confer to cancer cells a state of
oncogene addiction. Accordingly, MET is categorized as a driver
oncogene.
Among the different therapeutic approaches being exploited for
suppressing MET oncogenic activity, selective (capmatinib, tepo-
tinib) or non-selective (cabozantinib, crizotinib) small molecule
tyrosine kinase inhibitors (TKIs) are in advanced clinical testing.
Achieving a therapeutic success with MET-TKIs depends on
patients’ molecular selection, because only tumors truly addicted to
MET signaling may respond to MET blockade. In addition, pre-
clinical and clinical studies point to resistance as a vexing hurdle to
the therapeutic success of MET-TKIs (Ghiso & Giordano, 2013). It
follows that a detailed understanding of the signaling circuitries
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underpinning resistance must be viewed as an integral component
of the clinical development of MET-TKIs.
Several mechanisms of resistance to MET-TKIs have been
already reported and include (i) MET amplification (Cepero et al,
2010), point mutations (Bahcall et al, 2016), and over-expression
(Martin et al, 2014); (ii) KRAS amplification (Cepero et al, 2010);
(iii) bypass activation of downstream pathways by RTKs acting in
parallel to MET (Corso et al, 2010). Concerning the latter mecha-
nism, altered miRNA expression is increasingly recognized as a
strategy through which cancer cells reprogram their signaling circui-
tries in order to escape from pharmacological suppression of driver
oncogenes (Migliore & Giordano, 2013). Herein, we report that miR-
205 upregulation is sufficient to render MET-addicted tumors resis-
tant to structurally different MET-TKIs (non-selective such as crizo-
tinib, or selective such as PHA-665752 and JNJ-38877605) via
ERRFI1 targeting and consequent EGFR (epidermal growth factor
receptor) activation. Accordingly, combined MET and EGFR phar-
macological blockade reverts the adaptive resistance to MET-TKIs
imposed by miR-205 upregulation.
Results
Generation and characterization of MET-TKI-resistant cell lines
GTL16 (gastric carcinoma cells), SG16 (primary gastric carcinoma
cells), and EBC-1 (lung squamous cell carcinoma cells) are addicted
to MET (Corso et al, 2010; Apicella et al, 2016). This phenotype is
caused by MET amplification leading to MET over-expression and
constitutive activation (Cepero et al, 2010; Apicella et al, 2016). In
line, treatment of EBC-1, GTL16 and SG16 cells with crizotinib
(non-selective MET-TKI) or PHA-665752 and JNJ-38877605 (selec-
tive MET-TKIs), strongly impaired their viability (Fig 1A–C).
We generated EBC-1, GTL16, and SG16 cells resistant to crizo-
tinib, PHA-665752, or JNJ-38877605 by a stepwise dose escalation
protocol, eventually obtaining derivatives capable of normal growth
at drug concentrations roughly ten times higher than the IC50 calcu-
lated for parental cells (Fig 1A–C). Notably, all the resistant cells
were cross-resistant to the other MET-targeted drugs (Fig 1A–C).
To investigate a potential role for miRNAs in resistance to MET-
TKIs, pairs of sensitive and resistant GTL16, EBC-1, and SG16 cells
were profiled for miRNA expression. Out of 375 miRNAs examined,
we found that 201, 98, and 140 miRNAs were expressed by GTL16,
EBC-1, and SG16 cells, respectively. This compendium of expressed
miRNAs was used for further analyses. Unsupervised hierarchical
clustering of expressed miRNAs discriminated the three cell lines
(Fig EV1A). When comparing relative levels of expressed miRNAs
in each pair of sensitive/resistant cell lines, a single miRNA, namely
miR-205, was concordantly and abundantly upregulated in all of the
MET-TKI-resistant cells (Table 1). Real-time PCR analyses con-
firmed miR-205 upregulation (up to 130-fold) in resistant cells
(Fig EV1B–D). This datum was consolidated by the observation that
two additional MET-addicted cells lines, namely KATO II and SNU-
5, showed increased miR-205 expression upon becoming resistant to
MET-TKIs (Fig EV1E and F; and Appendix Fig S1A and B).
Since epigenetic regulation can modify miR-205 level (Hulf et al,
2013), we explored the possibility that differential methylation of
miR-205 genomic locus could contribute to the observed differences
of miR-205 expression in resistant versus wt cells. To this aim, we
investigated the methylation status of the miR-205 genomic region
(Appendix Fig S2A and B). As shown in Fig 1D, we observed that
the level of methylation of the CpG enriched region mapping to the
miR-205 locus was significantly lower in resistant cells when
compared to their wt counterpart. In fact, the CpG methylation level
at the miR-205 locus in resistant cells was comparable to that
observed in parental cells upon treatment with 5-Aza-20-deoxycyti-
dine, with CpG de-methylation leading to increased miR-205 expres-
sion (Fig 1E).
MiR-205 upregulation mediates resistance to MET-TKIs, which
is linked to reduced expression of the putative miR-205
target ERRFI1
As shown in Fig 2A–C and Appendix Fig S3A–C, miR-205 silencing
significantly reduced cell viability in all drug-resistant derivatives.
Conversely, ectopic expression of miR-205 in wt cells was capable
of increasing their viability at TKIs concentrations in the IC50 range
(Fig 2D–F and Appendix Fig S3D–F).
To further validate these in vitro results, we performed in vivo
experiments. To this end, GTL16 R-CRIZ cells transduced with either
control or anti-miR-205 lentivirus (Appendix Fig S4A) were injected
s.c. in NOD-SCID mice. Tumor-bearing mice were subjected to treat-
ment with crizotinib. As shown in Fig 2G, tumors generated by anti-
miR-205 transduced cells were highly sensitive to crizotinib treat-
ment, while controls remained resistant. In mirror experiments,
tumors generated by wt GTL16 cells engineered to over-express
miR-205 (Appendix Fig S4B) were refractory to crizotinib treatment,
while control tumors were highly sensitive (Fig 2H).
The above dataset is compatible with the hypothesis that miR-205
upregulation can cause MET-addicted cancer cells to acquire resis-
tance to MET-TKIs. This, in turn, raises the question of which among
miR-205 targets may determine the observed resistance phenotype.
In broad terms, resistance to TKIs may be caused by mutations of the
target kinase, resulting in reduced/abolished TKI binding, or bypass
activation of downstream pathway(s) despite enduring target block-
ade (Lackner et al, 2012). In general, MET kinase retained sensitivity
to inhibition by MET-TKIs in resistant cells even if this was not
complete. Treatment with MET-TKIs did not translate into significant
suppression of ERK and AKT activation in resistant cells, although in
CRIZ-resistant GTL16 cells AKT activation was not as high as in the
wt control (Fig 2I). Of note, activation of ERK and AKT was affected
marginally, or not at all, by drug withdrawal (Fig 2I), suggesting that
preservation of oncogenic signaling downstream to MET was not a
direct effect of MET-TKI administration.
In searching for mechanisms responsible for bypass signal activa-
tion, we found that expression of PTEN, a bona fide miR-205 target
gene (Cai et al, 2013), was not altered in resistant cells
(Appendix Fig S5), while EGFR, a well-known MET partner (Haura
& Smith, 2013), retained or even increased its expression/activity in
resistant cells (Fig 2I). No EGFR mutation/amplification was
detected in resistant cells. These data suggest a potential role for
non-mutational EGFR activation in fueling vicarious ERK and AKT
activation in MET-TKI-resistant derivatives subjected to MET
blockade.
A potential link between miR-205 upregulation and increased
EGFR activity emerged from the comparative analysis of RNA-Seq
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Figure 1. Characterization of MET-addicted cells rendered resistant to MET tyrosine kinase inhibitors.
A–C EBC-1 (A), GTL16 (B), and SG16 (C), either parental (wt) or resistant (-R) to the indicated MET-TKIs, were exposed to escalating concentrations of the indicated
drugs. Cell viability was measured after 72 h (CellTiterGlo) to derive IC50 values. Data are the mean of three independent experiments, each performed in
quadruplicate wells. PHA = PHA-665752; CRIZ = crizotinib; JNJ = JNJ-38877605; R-PHA = cells resistant to PHA-665752; R-CRIZ = cells resistant to crizotinib; R-
JNJ = cells resistant to JNJ-38877605.
D SG16 and EBC-1 genomic DNA from resistant and wt cells, untreated or treated with 5-Aza-20-deoxycytidine (5-AZA), was extracted and subjected to bisulfite
conversion. The miR-205 genomic region was amplified by PCR and pyrosequenced. The scatter dot plot represents the percentage of DNA methylation of miR-205
genomic region; each dot exemplifies the average of the methylation status of six CpGs (shown in Appendix Fig S2) analyzed in two technical replicates
(Squares = wt untreated cells; triangles = wt cells treated with 5-AZA (used as control); circles = resistant cells).
E MiR-205 expression was evaluated by RT–qPCR in SG16 and EBC-1 wt treated or not with 5-Aza-20-deoxycytidine (5-AZA). As shown, miR-205 level significantly
increased upon 5-AZA treatment. n = 3 per condition.
Data information: (A–C) Data are presented as mean  SD. Two-way ANOVA, Bonferroni’s multiple comparisons test was significant (P < 0.001) in wt versus resistant
cells. (D) Data are presented as median and 95% CI. ***P < 0.001; one-way-ANOVA, Bonferroni’s multiple comparisons test. (E) Data are presented as mean  SD.
***P < 0.001, two-tailed t-test.
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data obtained from wt and crizotinib-resistant pairs of both EBC-1
and GTL16 cells. Figure 2J and Appendix Fig S6 show that ERRFI1
(ERBB receptor feedback inhibitor 1) was one of the few putative
miR-205 targets, as predicted by the TargetScan algorithm (Agarwal
et al, 2015), to be downregulated in both EBC-1- and GTL16-resis-
tant cells (Cora’ et al, 2017). The ERRFI1 product (also named
MIG6) is an inducible feedback inhibitor of the EGFR/HER receptor
family (Anastasi et al, 2016). Genetic studies in the mouse have
pointed to an essential role of Errfi1 in restraining Egfr-dependent
cell proliferation in normal tissues as well as suppressing Egfr-
driven tumor formation (Anastasi et al, 2016). Mechanistically,
ERRFI1 binds to the EGFR activated kinase domain, thus suppress-
ing its catalytic activity. In addition, ERRFI1 instigates endocytosis/
degradation of the kinase-inactive EGFR molecules to which it binds
(Frosi et al, 2010). Hence, we surmised that ERRFI1 downregulation
consequent to miR-205 uprise could mediate an increase in EGFR
expression/activity (see Fig 2I) sufficient to fuel resistance to MET
blockade. In line, ERRFI1 expression was clearly lower in resistant
cells compared to their parental counterpart (Fig EV2A–C). GTL16
R-PHA cells stood out as the single exception, most likely because
KRAS amplification mediates the resistance of these cells to PHA-
665752 (Cepero et al, 2010). Ectopic ERRFI1 sufficed to re-sensitize
resistant cells to MET-TKIs both in vitro (Fig 3A and B; and
Appendix Fig S7A and B) and in vivo (Fig EV3A and B), with the
predictable exception of GTL16 R-PHA cells (Appendix Fig S7B).
Critically, ERRFI1 knockdown attenuated growth suppression of
parental EBC-1 and SG16 cells mediated by either crizotinib or JNJ-
38877605 (Fig 3C). We noted that ectopic ERRFI1 was not as effec-
tive as anti-miR-205 in restoring sensitivity to crizotinib in tumor
xenotransplants (compare Fig 2G with Fig EV3B). The most parsi-
monious explanation for this discrepancy is that while ERRFI1
appears to be the most critical miR-205 target in this context, other
miRNA targets may contribute to the development of the resistant
phenotype. The above data provide a causal link between loss of
ERRFI expression and the development of resistance to MET-TKIs in
MET-addicted cells. Interestingly, we observed that the miR-205/
ERRFI1/EGFR regulatory axis can operate also in not-addicted cells,
as ectopic miR-205 expression in A549 lung cancer cells resulted in
ERRFI1 downregulation and increased EGFR expression/activation
(Appendix Fig S8A and B).
ERRFI1 targeting by miR-205 increases EGFR activity, promoting
resistance to MET-TKIs
To investigate whether miR-205 is involved in ERRFI1 regulation,
we expressed ectopic miR-205 in EBC-1, GTL16, and SG16 wt cells.
This was sufficient to produce a decrease in ERRFI1 protein expres-
sion (Fig 3D). In a second set of experiments, we investigated the
regulation of a Luc-ERRFI1 reporter (in which the ERRFI1 30 UTR is
cloned downstream to the luciferase cDNA) in wt GTL16 cells that
express very low levels of endogenous miR-205. Figure 3E shows
that ectopic miR-205 significantly downregulated the luciferase
Table 1. Global miRNA expression measured by TaqMan low density array.
EBC1 R150 CRIZ EBC1 R250 PHA GTL16 R200 CRIZ GTL16 R300 PHA SG16 R250JNJ
miRNA
Fold
change miRNA
Fold
change miRNA
Fold
change miRNA
Fold
change miRNA
Fold
change
TOP 10
miRNAs
UPREGULATED
miR-205 53.1 miR-146a 1301.5 miR-205 1256.9 miR-205 1368.7 miR-339-3p 8.1
miR-27b 1.8 miR-205 115.4 miR-328 528.7 miR-125b 305.6 miR-339-5p 7.7
miR-27a 1.5 miR-27b 7.7 miR-133a 330.0 miR-501-3p 260.6 miR-148a 7.5
miR-193b 1.4 let-7a 4.6 miR-146a 245.8 miR-184 104.1 miR-375 6.9
miR-141 1.4 miR-422a 3.0 miR-125b 179.5 miR-146a 81.5 miR-205 5.8
miR-24 1.4 miR-146b-5p 2.7 miR-642 94.6 miR-99a 58.1 miR-328 5.4
let-7a 1.2 miR-24 2.7 miR-423-5p 93.9 miR-495 46.9 miR-9 5.3
miR-19a 1.2 miR-27a 2.3 miR-579 91.8 miR-133a 41.0 miR-10a 5.2
miR-9 1.1 miR-598 2.3 miR-125a-3p 50.4 miR-616 37.3 miR-139-5p 4.9
miR-365 1.1 miR-200a 2.3 miR-142-3p 48.8 miR-15a 27.6 miR-23b 4.7
TOP 10
miRNAs
DOWNREGULATED
miR-196b 0.1 miR-100 0.1 miR-363 0.0 miR-450b-5p 0.0 miR-106b 0.3
miR-125b 0.1 miR-99a 0.1 miR-379 0.2 miR-363 0.0 miR-155 0.4
miR-146a 0.1 miR-125b 0.1 miR-517c 0.2 miR-22 0.1 miR-93 0.4
miR-100 0.2 miR-886-5p 0.1 miR-410 0.2 miR-190 0.1 miR-25 0.5
miR-99a 0.2 miR-139-5p 0.2 miR-518f 0.4 miR-517c 0.1 miR-100 0.6
miR-345 0.2 miR-138 0.2 miR-190 0.4 miR-150 0.2 miR-99a 0.7
miR-886-3p 0.2 miR-886-3p 0.3 miR-20b 0.4 miR-452 0.2 miR-345 0.7
miR-339-5p 0.3 miR-222 0.4 miR-505 0.5 miR-449b 0.3 miR-10b 0.7
miR-212 0.3 has-miR-155 0.4 miR-9 0.5 miR-362-3p 0.3 miR-320 0.7
miR-138 0.3 miR-484 0.4 miR-376a 0.5 miR-338-3p 0.4 miR-18a 0.7
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signal in Luc-ERRFI1-transfected cells, an effect comparable to that
observed upon expression of miR-200c, a validated ERRFI1-targeting
miRNA (Adam et al, 2009). Deletion or mutation of the predicted
miR-205 targeting sequence in the Luc-ERRFI1 reporter strongly
reduced luciferase downregulation by ectopic miR-205 (Fig 3F),
pointing to direct regulation of ERRFI1 by miR-205. Finally, and in
line with ERRFI1 acting as EGFR inhibitor, ectopic miR-205 mark-
edly increased EGFR expression/activation in EBC-1 and SG16 cells
(Fig 3G). A more modest effect was observed in GTL16 cells.
Increased EGFR activity, consequent to miR-205-dependent
downregulation of ERRFI1, was largely responsible for resistance to
MET-TKIs, because the clinically approved EGFR-TKI afatinib
greatly alleviated resistance of EBC-1 and SG16 cells to MET-TKIs in
a dose-dependent manner (Fig 3H and I). A less pronounced effect
was observed also in GTL16 cells resistant to crizotinib
(Appendix Fig S9). Overall, the activity of afatinib in individual
resistant cell lines correlated with the magnitude of relative changes
in cell proliferation rates observed upon miR-205 downregulation
(Fig 2A–C); afatinib activity in resistant cells also correlated with
relative variations of pEGFR levels detected in the corresponding
parental cells upon miR-205 over-expression (Fig 3G). Finally,
GTL16 R-PHA growth was not affected by afatinib, consistent with
KRAS amplification being causative of resistance to PHA-665752
(Appendix Fig S9).
Concurrent ERRFI1 downregulation and miR-205 over-expression
are identified in a patient with acquired MET-TKI resistance
Motivated by the above findings, we endeavored to investigate
whether alterations of the miR-205-ERRFI1 axis can enforce clinical
resistance to MET-TKIs. Because MET-TKIs are not yet approved for
routine clinical use, we could not have access to specimens
from patients harboring MET-driven tumors and undergoing
treatment with MET-TKIs. However, we could study two cases—a
BRAF-mutated CRC (patient #1) and an EGFR-mutated NSCLC
(patient #2)—with documented MET-driven acquired resistance to
the respective target therapy. Of note, administration of a MET-TKI
led in both cases to a partial response followed by relapse.
◀ Figure 2. miR-205 modulates tumor cell sensitivity to MET-TKIs.A–C MiR-205 expression was silenced by transfection of either anti-miR-205 or control antagomiR (Ctrl) in EBC-1 (A), GTL16 (B), and SG16 (C) resistant cells. Resistant
cells were grown in the presence of the TKI to which they are resistant; viability was assessed after 72 h by CellTiterGlo. n = 4 per condition.
D–F MiR-205 or a control miRNA (Ctrl miR, a random miRNA sequence) was over-expressed in parental (wt) EBC-1 (D), GTL16 (E), and SG16 (F) cells. Cells were grown
for 72 h in the presence of MET-TKIs at the indicated doses. Viability was evaluated as above. n = 4 per condition.
G GTL16 R-CRIZ cells transduced with pCDH-anti-miR-205 or pCDH (control vector) were subcutaneously injected in NOD/SCID mice. Mice were treated with
crizotinib (25 mg/kg), and tumor volume was monitored for 18 days as indicated. n = 6 per condition.
H GTL16 wt cells transduced with pCDH-miR-205 or with the control vector (pCDH) were injected in NOD/SCID mice. When tumors reached an average volume of
around 150 mm3, treatment with either crizotinib (12.5 mg/kg) or vehicle was started. Tumor volume was monitored for 18 days as indicated. n = 6 per condition.
I Western blot analysis of EBC-1, GTL16, and SG16 cells, either parental (wt, untreated or treated for 2 h with the indicated TKIs) or TKI-resistant (either in the
presence or absence of the TKIs to which they are resistant). Cell lysates were probed with the indicated antibodies. Actin was used as loading control (one actin
panel for each WB performed/cell line). Drug abbreviation is as shown in Fig 1.
J The transcriptome of crizotinib-sensitive/resistant pairs of GTL16 and EBC-1 cells was determined by RNA-Seq. The mRNA heatmap shows the expression levels of
the predicted miR-205 targets (TargetScan 7.1) downregulated in resistant versus wt cells. For each gene, the log2 of the RSEM expected counts was converted to
the log2 ratio against the global median expression of the gene in all samples. Log2 ratio values were loaded in GEDAS software to perform hierarchical clustering
analysis and represent data in a heatmap. Units (1.5 to +1.5) represent the log2 ratio against the median. Red and blue colors represent the highest and lowest
ends of mRNA expression levels, respectively.
Data information: (A–H) Data are presented as mean  SD. Asterisks: ***P < 0.001; **P < 0.01; *P < 0.05. Two-tailed t-test was used for panels (A–C, F); two-way
ANOVA, Bonferroni’s multiple comparisons test was used for panels (D, E, G, H).
Source data are available online for this figure.
▸Figure 3. ERRFI1 is the main miR-205 target responsible for resistance to MET-TKIs.A, B EBC-1 (A) and SG16 (B) resistant cells were transduced with either empty (pCDH) or ERRFI1-encoding (pCDH ERRFI1) recombinant lentivirus stocks. Resistant cells
(R-CRIZ, R-PHA, R-JNJ) were grown in the presence of the TKIs to which they are resistant. As control, wt cells were grown in the absence (NT) or in the presence of
the indicated MET-TKIs. Viability was assessed by CellTiterGlo 72 h after plating. n = 4 per condition.
C ERRFI1 expression was silenced in EBC-1 and SG16 wt cells by transfection of either control (siCtrl) or ERRFI1-targeting siRNA pools. Cells were treated with
MET-TKIs at concentrations averaging the respective IC50; viability was evaluated 72 h later. n = 4 per condition.
D Immunoblot analysis of ERRFI1 in cell lines expressing ectopic miR-205. Actin was used as total protein loading control. The column chart shows the ratio between
the ERRFI1 and actin band intensities as quantified by ImageJ software.
E GTL16 wt cells were co-transfected with the Luc-ERRFI1 reporter plasmid along with the indicated miRNAs. Data are computed from six independent experiments
and expressed as arbitrary units (RLU), one being the control value obtained in cells expressing a non-targeting miRNA. n = 6 per condition.
F GTL16 wt cells were co-transfected with miR-205 and the Luc-ERFFI1 reporter, either in wt or delta, or mutated configuration. Data are computed from three
independent experiments and expressed as in (E). n = 3 per condition.
G Western blot analysis of EGFR expression and activation (pEGFR) in wt EBC-1, GTL16, and SG16 cells transfected with a control miRNA (Ctrl) or miR-205. Actin was
used as total protein loading control. Column chart shows the ratio between the pEGFR and actin band intensities as quantified by ImageJ software.
H, I Viability of EBC-1 (H) and SG16 (I) cells, either wt or resistant to the indicated MET-TKIs, following a 72 h incubation with escalating concentrations of afatinib.
Resistant derivatives were co-treated with the MET-TKI to which they are resistant. n = 4 per condition.
Data information: (A–C, E, F, H, I) Data are presented as mean  SD. ***P < 0.001; **P < 0.01; *P < 0.05, n.s. not significative. Two-tailed t-test (A–C, F), one-way ANOVA
(E), two-way ANOVA, Bonferroni’s multiple comparisons (H, I).
Source data are available online for this figure.
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In patient #1 (whose clinical history is reported in Pietrantonio
et al, 2016; Oddo et al, 2017), IHC did not reveal significant dif-
ferences in ERRFI1 levels when acquired resistance to MET plus
BRAF inhibition became manifest (Fig EV4). Interestingly, MET
hyper-amplification was reported as causative of resistance to MET
blockade in this patient (Oddo et al, 2017).
In patient #2, whose clinical history is summarized in
Fig EV5, IHC analysis showed that ERRFI1 expression was
decreased in cells that became resistant to dual MET/EGFR block-
ade compared to cells resistant to single agent erlotinib [compare
panel (b) with panel (a) in Fig 4A]. Notably, ERRFI1 levels in
(a) and (b) were anti-correlated to coincident changes in miR-205
expression (Fig 4B). Because it occurred in the context of ongo-
ing gefitinib administration (Fig EV5), we assume that loss of
ERRFI1 expression was sufficient to enhance signaling by a frac-
tion of EGFR del746-750 escaping gefitinib blockade. This is
consistent with the notion that Errfi1 is haploinsufficient in a
mouse model of EGFR del746-750-driven NSCLC (Anastasi et al,
2016). The above data provide a proof of concept that anti-corre-
lated oscillations of miR-205 and ERRFI1 expression do occur in
a clinical context of resistance to a MET-TKI, predictably enforc-
ing an EGFR-dependent mechanism of refractoriness to MET
blockade.
Discussion
Several MET-TKIs are in advanced clinical development; however,
as in the case of TKIs targeting other oncogenic RTKs, the emer-
gence of resistance poses a serious challenge to achieving a long-
term benefit from MET-TKIs (Haura & Smith, 2013). Here, we
describe a novel mechanism of adaptive resistance to three struc-
turally different MET-TKIs, which entails upregulation of EGFR
activity consequent to miR-205-driven reduction in ERRFI1 expres-
sion. This is yet another example of how versatile and effective
miRNA regulation might be in shaping the adaptation of cancer cells
to external perturbations. As for mechanism/s involved in miR-205
upregulation, our initial studies suggest a role for de-methylation of
regulatory sequences in the miR-205 genomic locus.
Our demonstration that miR-205-driven ERRFI1 loss is sufficient
to confer vicarious oncogenic properties to EGFR signaling is
congruent with (i) biochemical studies that assign to ERRFI1 a role
as pan-ERBB inhibitor; (ii) genetic analyses in the mouse that have
nominated Errfi1 as a tumor suppressor; (iii) biological experiments
in glioblastoma, NSCLC, and pancreatic carcinoma cells that point
to ERRFI1 loss as key mechanism in sustaining oncogenic addiction
to EGFR signaling (reviewed in Anastasi et al, 2016). Interestingly,
we did not observe a consistent miR-205 increase in
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Figure 4. Concomitant ERRFI1 downregulation and miR-205 over-expression are identified in a patient with acquired resistance to MET-TKIs.
A Immunohistochemical analysis of ERRFI1 expression in biopsies taken from patient #2 upon onset of resistance to EGFR therapy (a) and, subsequently, to combined
anti-EGFR/MET treatment (b). Note that (a) and (b) refer to the stages of patient’s clinical history outlined in Fig EV5. Scale bar = 0.25 mm.
B MiR-205 expression was evaluated by RT–qPCR on FFPE-derived RNA extracted from samples (a) and (b). n = 3, average  SD. **P < 0.01, two-tailed t-test.
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EGFR-addicted cells rendered resistant to different EGFR inhibitors
(Appendix Fig S10); this suggests that miR-205 upregulation might
operate selectively in rewiring EGFR activity in the context of bypass
resistance to non-EGFR TKIs.
Remarkably, the above mechanism of resistance to MET-TKIs,
albeit not genetically driven, is therapeutically actionable, because
EGFR blockade suffices to restore sensitivity to MET-TKIs. Although
the clinical use of EGFR TKIs is essentially restricted to EGFR-
mutated NSCLC, our data imply that selected contexts of clinical
resistance to MET-TKIs may represent a prime example of beneficial
targeting of wt EGFR. We duly caution that further work on a larger
scale is needed to validate our model of deregulated miR-205-
ERRFI1-EGFR axis in MET-addicted tumors. We envision that patho-
logical samples obtained from patients enrolled in ongoing clinical
studies (e.g., the NCT02414139 trial that is evaluating the efficacy of
the MET-TKI capmatinib in NSCLC patients selected for the presence
of MET deregulation) will be invaluable for future studies.
The present study expands on previous work by the Sidranski’s
group (Izumchenko et al, 2014), who showed that ERRFI1 targeting
by miR-200 (a known ERRFI1 targeting miRNA) heightens EGFR
signaling and consequently generates a condition of EGFR addiction
in lung and pancreas cancer cells expressing wt EGFR. We hypothe-
size that the dominant role of a given miRNA in ERRFI1 regulation
may reflect variables such as tumor cell identity, stage of tumor
evolution, and therapeutic setting. Previous work also pointed to
miR-200 and ERRFI as reliable surrogate markers of addiction to wt
EGFR (Anastasi et al, 2016). This is notable, as routine evaluation
in the clinical laboratory of EGFR Tyr-phosphorylation is still techni-
cally challenging. In the setting of MET-addicted cancers, our work
anticipates that assessing ERRFI1 and miR-205 expression could
guide the identification of patients that develop adaptive EGFR-
driven resistance to MET-TKIs.
MET amplification occurs in up to 18% of EGFR-mutated NSCLC
cases that develop resistance to approved EGFR TKIs (Engelman &
Ja¨nne, 2008). Previous work (Apicella et al, 2016), along with pre-
clinical and clinical data presented herein, supports the view that
EGFR activation can in turn substitute for MET signaling in MET-
driven cancer cells. Thus, MET and EGFR appear to be bound by a
mutual rescue agreement whenever any of the two incurs in pharma-
cological blockade. In line with this proposition and based on promis-
ing proof-of-concept studies (Corso et al, 2010; Haura & Smith, 2013),
the addition of MET-TKIs to EGFR inhibitors is currently under clinical
investigation in the setting of MET-driven acquired resistance to EGFR
blockade. More in general, our data suggest that upfront co-targeting
of MET and EGFR could be a viable option to delay/prevent/revert the
onset of TKI resistance in at least a fraction of MET- or EGFR-addicted
tumors. While the identification of robust biomarkers capable of iden-
tifying tumor subsets that may benefit from wt EGFR targeting is a
major challenge ahead, the present work provides a mechanism-based
rationale for future clinical and translational research.
Materials and Methods
Patient care and specimen collection
Clinical data of patient #1 were reported in references (Pietrantonio
et al, 2016; Oddo et al, 2017).
At diagnosis, patient #2 was a 52-year-old male with metastatic
EGFR exon 19-deleted lung adenocarcinoma. Tumor samples were
collected in accordance with an Institutional Review Board-
approved protocol, to which the patient provided written informed
consent. Informed consent was obtained from all subjects. The
experiments conformed to the principles set out in the WMA Decla-
ration of Helsinki and the Department of Health and Human
Services Belmont Report. Initial therapy with erlotinib was given as
per standard practice, whereas gefitinib/capmatinib was subse-
quently administered as experimental combination (clinicaltrials.gov
identifier: NCT01610336).
Animal studies
Animal handling and experimentation was performed in accordance
with the European Union directives and the Italian Guidelines for
Care and Use of Laboratory Animals. All animal procedures were
approved by the Ethics Committee of the Candiolo IRCC and the Ital-
ian Ministry of Health. All experiments were performed in 7- to 8-
week-old female NOD-SCID mice purchased from Charles River
(Milan, Italy) and maintained on a 12 h light/dark cycle at 22°C. In
each animal experiment, mice were randomly assigned to each
group.
1 × 106 wt or R-CRIZ GTL16 cells were injected subcutaneously
into the right posterior flanks of 6-week-old immunodeficient NOD/
SCID female mice. Mice carrying tumors from wt GTL16 cells were
randomized and treated or not with crizotinib (12.5 mg/kg) when
tumors reached a volume of around 150 mm3, while for animals
injected with R-CRIZ GTL16 cells crizotinib administration (25 mg/
kg) started from the beginning. Tumor size was evaluated by caliper
measurements, and approximate volume of the mass was calculated
using the formula 4/3 p (D/2) (d/2)2, where d and D are the minor
tumor axis and major tumor axis, respectively. Crizotinib (PF-
02341066) was obtained from the Candiolo IRCCs Pharmacy that
collected small amount of drugs left over after treating
patients. Experiments were not performed in blind.
Cell cultures, plasmids, and compounds
HEK293T, A549, and SNU-5 cell lines were obtained from ATCC
(Manassas, VA, USA); EBC-1 from Japan Cancer Research Resources
Bank (Ibaraki, Osaka, Japan); KATO II cells were kindly provided
by Dr. Yitzhak Zimmer, University of Bern. GTL16 and SG16 were
described in references (Migliore et al, 2008; Apicella et al, 2016).
The genetic identity of the cell lines was periodically checked by
short tandem repeat profiling (Cell ID, Promega, Madison, Wiscon-
sin, USA). Mycoplasma testing is performed routinely using the PCR
Mycoplasma Detection Kit (Applied Biological Materials Inc., Rich-
mond, BC, Canada).
PHA-665752 (PHA) and afatinib were from Selleckchem
(Munich, Germany); crizotinib (CRIZ) from Sequoia Research Prod-
ucts (Pangbourne, United Kingdom). The MET inhibitor JNJ-
38877605 (JNJ) was provided by Janssen Pharmaceutica NV
(Beerse, Belgium). To generate resistant cell lines, we used a step-
wise dose escalation method, starting from a dose close to the cell
viability IC50 followed by stepwise escalations over a 6- to 12-month
period. Established resistant sublines were maintained in culture
with the highest drug dose compatible with full viability and
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proliferation rates similar to those of parental cells. All the assays
involving resistant cells were performed in the presence of the TKI
to which they had been rendered resistant, i.e., at the maximum
dose reached at the end of the dose escalation protocol.
The ERRFI1 expression vector was described elsewhere (Frosi
et al, 2010). Lentiviral construct for anti-miR-205 was kindly
provided by Dr. Chun-Ju Chang, Purdue University. Luciferase
reporter vector was obtained cloning the full ERRFI1 30UTR
sequence (nt. 1639-3144) downstream to the luciferase gene in
pMIR-REPORT vector (Thermo Fisher, Waltham, MA, USA). The
delta ERRFI1 30UTR vector was produced by deleting nt 2923–3144
of the ERRFI1 30UTR, containing the unique miR-205-5p target
sequence, by single digestion with PmeI. MUT-ERRFI1-30UTR vector
was produced as follows. A SacI-NotI fragment encompassing the
ERRFI1 30UTR sequence was excided from pMIR-Report-ERRFI1 and
cloned into the pBluescript (BS) plasmid. The resulting vector, pBS-
hERRFI1 30UTR, was used as a template for mutagenesis using the
Q5 site-directed mutagenesis kit (New England Biolabs, NEB). The
mutagenized insert was transferred back into pMIR-Report. The
following primers, designed according to the NEB software NEBase
Changer (https://nebasechanger.neb.com), were used in the muta-
genesis reaction:
Forward Primer: 50-TATGAACTAAccGcgaGTTAAAACATGCTTAA
GAAAAATGCAC-30
Reverse Primer: 50-CTAAAATATAATAAGCTTTAAATAGC-30
In detail, the ATGAAGG sequence (corresponding to position
2,980–2,986 of the ERRFI1 cDNA sequence) was mutagenized to
ccGcgaG (base changes in lower case). Mutagenesis and sub-cloning
steps were sequence verified.
Protein extraction and Western blot
For Western blot analysis, cells were lysed in LB buffer [2% SDS,
0.5 mol/l Tris–HCl (pH 6.8)]. Western blots were performed accord-
ing to standard methods. Primary antibodies were as follows:
anti-phospho-MET#3077 (Y1234-5); anti-AKT#9272; anti-phospho-
AKT#4060 (S473); anti-MAPK#9102; anti-phospho-MAPK#9101
(Thr202/Tyr204); anti-PTEN#9188 from Cell Signaling (Leiden, The
Netherlands); anti-b-actin #A3854 from Sigma; anti-phospho-
EGFR#5644 (Y1068) from Abcam (Cambridge, UK); anti-EGFR
(sc71033); anti-myc (sc-40B) and anti-HER2 (sc284) from Santa
Cruz; and anti-ERRFI1 was described in Frosi et al (2010). All anti-
bodies were used at a dilution of 1:1,000, except for anti-actin
(1:50,000) and anti-ERRFI1 (1:2,500). TKIs were added 2 h before
cell lysis.
Gene transfer procedures and cell viability assay
For cell viability assays, cells were seeded in quadruplicate well
in 96-well culture plates (3–5 × 103 cells/well), in the presence
of the indicated drugs. After 72 h, cell viability was measured
using the Cell Titer-Glo Luminescent Cell Viability Assay
(Promega).
EBC-1, GTL16, and SG16 cells were transfected with siRNAs/
miRNAs using Lipofectamine 2000 (Thermo Fisher). Transfection
reagents plus siRNAs/miRNAs at final concentration of 20 nM were
used according to manufacturer’s protocols. Cell viability was
measured 72 h after transfection. ERRFI1 silencing was achieved
using SMARTpool ON-TARGET plus siRNA (Dharmacon, Lafayette,
CO, USA). Pre-miRTM miRNA Precursor for miR-205-5p (#PM11015)
over-expression studies was from Thermo Fisher. Anti-miR-205-5p
(#4101508-001) miRCURY LNATM microRNA inhibitor was from
Exiqon (Vedbaek, Denmark). Lentiviruses were produced as
described in Vigna and Naldini (2000). Cells were transduced with
virus titers corresponding to 40 ng/ml p24.
mRNA, miRNA, and genomic DNA studies
Total RNA from cultured cells was extracted using miRNeasy extrac-
tion kit (Qiagen, Venlo, the Netherlands). For RNA extraction from
FFPE, Maxwell RSC RNA FFPE Kit (Promega) was used according
to manufacturer’s protocol, starting from 10-lm-thick sections.
Retrotranscription and real-time PCR were performed as in Migliore
et al (2008). Genomic DNA was extracted using QIAamp DNA Mini
Kit (Qiagen). Fifty ng of gDNA was amplified and analyzed using
TaqMan Gene Expression Master Mix (Thermo Fisher).
EGFR exons from 17 to 28 were sequenced using the following
primers: amplicon 1 fw1: 50-CTCCTCTTGCTGCTGGTGGT-30 rev1:
50-ATCTTGACATGCTGCGGTGT-30; amplicon 2 fw2: 50-AAAGGGCA
TGAACTACTTGGAG-30 rev2: 50-ATGAGGTACTCGTCGGCATC-30
amplicon 3 fw3: 50-AGAATGCATTTGCCAAGTCCTAC-30 rev3: 50-GC
TGGACAGTGTTGAGATACTCG-30; amplicon 4 fw4: 50-TGCCTGAA
TACATAAACCAGTCC-30, rev4: 50-TCTGTGGGTCTAAGAGCTAAT
GC-30). Mutational analysis was performed via PCR amplification of
2 ll of cDNA using AmpliTaq Gold kit (Promega). PCR products
were purified using AMPure (Agencourt Bioscience Corp., Beckman
Coulter S.p.A, Milan, Italy) according to manufacturer’s procedures
and analyzed with a 3730 DNA Analyzer, ABI capillary elec-
trophoresis system (Thermo Fisher).
MiRNA expression profiling was performed using TaqMan Low
Density Arrays (TLDA) (Array A) following manufacturer’s instruc-
tions (Thermo Fisher). Each sample was run in biological duplicate.
For each sample, 377 miRNAs were profiled and 98 miRNAs were
selected;miRNAs showing anomalies (flag) during amplification and/
or a CT value higher than 32 (indicating a low level of expression) in at
least two out of the three cell lines analyzedwere excluded fromanaly-
sis. For miRNA analysis, expression data from each array were first
normalized to the internal control RNU48; subsequently, the DDCT
method was used to evaluate the relative expression level (fold
change) of miRNAs in each resistant subline versus the respective
parental cell line. Delta-ct valueswere loaded inGEDAS software (Fu&
Medico, 2007) to perform hierarchical clustering analysis and repre-
sent data in aheatmap.
Methylation analysis
Sub-confluent EBC-1 and SG16 cells were treated with 5-Aza-20-
deoxycytidine (A3656- Sigma, Darmstadt, Germany) at a concentra-
tion of 1 lM for 72 h and 0.5 lM for 48 h, respectively.
For CpG methylation analysis at the miR-205 locus, 600 ng of
genomic DNA was subjected to bisulfite conversion using EpiTect
Bisulfite Kit (Qiagen) and subsequently PCR-amplified using the
forward primer 50-TGGAGTGAAGTTTAGGAGGTATGG-30 and biotiny-
lated reverse primer 50-CACACTCCAAATATCTCCTTCATT-30. The PCR
mix contained 3 mM MgCl2, 0.4 mM deoxynucleosidetriphosphates
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dNTPs, 1 U of Platinum Taq DNA Polymerase (Invitrogen), 0.6 lM
forward primer, 0.4 lM biotinylated reverse primer, and 20 ng of
bisulfite-treated DNA in a final volume of 25 ll. PCR was carried
out for a total of 50 cycles (30 s at 94°C, 30 s at 55°C, and 30 s at
72°C) in a PCR System 9700 (Applied Biosystems). Pyrosequencing
analysis was performed according to the manufacturer’s instruc-
tions using PyroMark Gold Q96 Reagents (Qiagen) and the
sequencing primer 50-GAGTTGATAATTATGAGGTT-30 (0.5 lM in
40 ll of annealing buffer).
Immunohistochemistry
Immunohistochemistry was performed on FFPE tissue sections
using the Dako Autostainer link platform. Deparaffinization, rehy-
dration, and target retrieval were performed in the PT Link (Dako
PT100). Slides were then processed on the Autostainer Link 48
(Dako AS480) using an automated EnVision FLEX (DAKO) staining
protocol. The anti-ERRFI1 mAb clone E2 was used at 5 lg/ml (Frosi
et al, 2010). Positive and negative controls were included for each
immunohistochemical run. Pictures were acquired with the Leica
Assistant Suit (LAS EZ) Software.
RNA-Seq
Total RNA from crizotinib-resistant and parental GTL16 and EBC-1
cells was subjected to high-throughput sequencing for long poly-A+
RNAs. Two biological replicates from each cell line were analyzed.
RNA sequencing was performed in an Illumina NextSeq500
sequencer, obtaining a mean of 75 million 75 bps-single reads per
sample, with a stranded protocol. The Bowtie program (Langmead
et al, 2009) was used to align reads to the reference human hg19
genome. Annotations provided by Ensembl GRCh37 and GENE-
CODE 19 were set as reference for the RSEM computational pipeline
(Li & Dewey, 2011) used for quantification of gene expression
levels. The EBseqtool (Leng et al, 2013) was used to evaluate modu-
lated genes, with | FC | > 2 and FDR < 0.1 as parameters to define
the statistical significance of differential gene expression. Targets of
hsa-miR-205 were extracted from the TargetScan database, version
7.1 (Agarwal et al, 2015).
Data availability
The RNA-Seq data from this publication have been deposited to the
GEO database (https://www.ncbi.nlm.nih.gov/geo/) and assigned
the accession identifier GSE114406 (https://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE114406). Raw sequence data are
available throughout the NCBI Sequence Read Archive (https://
www.ncbi.nlm.nih.gov/sra), with accession number: PRJNA451125
(https://www.ncbi.nlm.nih.gov/bioproject/PRJNA451125/)§.
Statistical analyses
Statistical analyses were performed with the GraphPad Prism soft-
ware 7.02. One-way ANOVA or two-way ANOVA was followed
by Bonferroni’s multiple comparisons test as indicated in
figure legends. No sample was excluded from the analysis.
Graphs represent the mean, with error bars showing the SD.
Shapiro–Wilk test was used to assess normality of data distribu-
tions. Statistical significance: *P < 0.05; **P < 0.01; ***P < 0.001.
All P-values for main figures, tables, Expanded View figures and
Appendix supplementary figures can be found in Appendix Figs
S11–S13.
Expanded View for this article is available online.
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The paper explained
Problem
Genomics-based precision cancer medicine is predicated upon the
notion that (a) genetic alterations of so-called driver oncogenes are
necessary to sustain cancer growth and (b) pharmacological targeting
of driver oncogenes is deleterious to cancer growth. This has led to
the successful development and clinical approval of “smart drugs”
targeted to driver oncogenes. A major class of these “smart drugs” is
represented by oncogenic receptor tyrosine kinase inhibitors (referred
to as TKIs). However, the possibility of achieving long-lasting
responses to TKI treatment in the clinic is often limited by the occur-
rence of drug resistance, a process whereby cancer cells escape from
inhibition of their driver oncogenic receptor tyrosine kinase (RTK)
which they depend on. Understanding ways and means through
which cancer cells become refractory to TKIs is vital to circumvent
resistance in the clinic.
Results
The MET RTK has been nominated a driver oncogene in several tumor
types, including lung and gastric carcinomas, with MET-TKIs being in
advanced clinical development. Here, we report the discovery of a
mechanism through which cancer cells become resistant to a number
of structurally unrelated MET-TKIs. Specifically, we show that resistant
cells upregulate the expression of miR-205, a non-coding RNA that
inhibits the expression of a gene named ERRFI1. A known function of
the ERRFI1 gene product is that of inhibiting the activity of the
epidermal growth factor receptor (EGFR) RTK. Thus, the miR-205-
mediated reduction in ERRFI1 expression ends up increasing EGFR
activity, which drives the activation of a bypass signaling pathway,
allowing MET-TKI-targeted cells to elude MET inhibition. Experimen-
tally, this mechanism of resistance could be reverted by a combina-
tion therapy with MET and EGFR TKIs.
Impact
Our work suggests that miR-205 upregulation and attendant loss of
ERRFI1 expression flags the occurrence of an EGFR-driven mechanism
of secondary resistance to MET-TKIs. Several clinically approved EGFR
TKIs are already available; thus, our work has uncovered a therapeuti-
cally actionable mechanism of adaptive resistance to MET-TKIs.
§Correction added on 7 September 2018 after first online publication: the accession ID of the raw sequence data has been updated.
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